Abstract
Annual Review of Pharmacology and Toxicology
Vol. 48:
257-276
(Volume publication date February 2008)
(doi:10.1146/annurev.pharmtox.48.113006.094731)
First published online as a Review in Advance on September 17, 2007Epigenetics and Complex Disease: From Etiology to New Therapeutics Carolyn Ptak and Arturas PetronisThe Krembil Family Epigenetics Laboratory, Center for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8; email: arturas_petronis@camh.net Epigenetics is a new development in complex non-Mendelian disease, which may not only uncover etiologic and pathogenic mechanisms but may also provide the basis for the development of medications that would target the primary epigenetic causes of such diseases. Such epigenetic drugs would be novel, potentially possessing substantially higher therapeutic potential and a much lower rate of adverse effects in comparison to current symptomatic treatments. A collection of epigenetic drugs already exist at various stages of development and, although their effectiveness has yet to be maximized, they show great promise in the treatment of cancer, psychiatric disorders, and other complex diseases. Here we present a review of the epigenetic theory of complex disease and an evaluation of current epigenetic therapies, as well as predictions of the future directions in this expanding field. Acronyms and Definitions Complex disease : conditions caused by a combination of genetic, epigenetic, and environmental factors that do not follow Mendelian/monogenic inheritance DNMT : DNA methyltransferase Epimutation : epigenetic changes that cause or predispose an organism to a disease HAT : histone acetyltransferase HDAC : histone deacetylase HDACi : histone deacetylase inhibitor Histone : basic proteins around which DNA is wrapped in higher-order chromatin structures MBD : methyl-binding domain MeCP2 : methyl-CpG-binding protein 2 Monozygotic (MZ) twins : genetically identical twins arising from a single zygote SCFA : short-chain fatty acid Most recent citing papers (via CrossRef)GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability Erminio Costa, Ying Chen, Erbo Dong, Dennis R Grayson, Marija Kundakovic, Ekrem Maloku, William (Brad) Ruzicka, Rosalba Satta, Marin Veldic, Adrian Zhubi, Alessandro Guidotti Expert Review of Neurotherapeutics 9(1):87-98 (2009) Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response Expert Review of Clinical Pharmacology 2(1):55-65 (2009) Prospects for Epigenetic Epidemiology American Journal of Epidemiology 169(4):389-400 (2009) Epigenetics and the nervous system Annals of Neurology 64(6):602-617 (2009) A simple algorithm for quantifying DNA methylation levels on multiple independent CpG sites in bisulfite genomic sequencing electropherograms Nucleic Acids Research 36(11):e64-e64 (2008)
|
|
|
Users who read this review also read:
| Moshe Szyf Annual Review of Pharmacology and Toxicology. Volume 49, Page 243-263, Feb 2009 Abstract
| Full Text
| PDF (253 KB)
|
Add to Favorites
| Related | |
| Rima Kaddurah-Daouk, Bruce S. Kristal, Richard M. Weinshilboum Annual Review of Pharmacology and Toxicology. Volume 48, Page 653-683, Feb 2008 Abstract
| Full Text
| PDF (698 KB)
|
Add to Favorites
| Related | |
| Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, Peter A. Jones Annual Review of Medicine. Volume 59, Page 267-280, Feb 2008 Abstract
| Full Text
| PDF (218 KB)
|
Add to Favorites
| Related | |
| Christine A. Iacobuzio-Donahue Annual Review of Pathology: Mechanisms of Disease. Volume 4, Page 229-249, Feb 2009 Abstract
| Full Text
| PDF (1044 KB)
|
Add to Favorites
| Related | |
|
|